** Medical device maker GeneDx's shares WGS.O surge 19.3% to $91.1 premarket
** Co posts Q4 revenue of $95.3 mln, beating analyst est of $82.23 mln as per data compiled by LSEG
** Co forecasts 2025 revenue in the range of $350 mln to $360 mln, higher than analysts' expectations of $338.8 mln
** WGS makes medical devices used to diagnose rare genetic disorders, epilepsy and autism
** Co reports adj Q4 net income of $16.8 mln vs analyst est of $2.9 mln
** Stock had risen 17.3x in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.